October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Adil Aftab: Acute VTE Treatment and Anticoagulation Considerations in Renal Dysfunction

Adil Aftab/LinkedIn

Sep 10, 2026, 14:30

Adil Aftab: Acute VTE Treatment and Anticoagulation Considerations in Renal Dysfunction

Adil Aftab, Postgraduate Trainee at People’s University of Medical and Health Sciences for Women, Nawabshah, shared a post on LinkedIn:

“Acute DVT or PE (VTE) Treatment, Anticoagulation and Renal Function

Anticoagulation is the cornerstone of acute venous thromboembolism management. Choosing the right agent requires careful consideration of renal function, bleeding risk, drug interactions, clinical stability, and patient preference.

This quick reference chart highlights commonly used options including Apixaban, Rivaroxaban, Edoxaban, Dabigatran, LMWH, and UFH, with important renal function considerations.

Key clinical points:

Use Cockcroft Gault CrCl when making anticoagulant dosing decisions.
Reassess renal function regularly.
UFH is often preferred when renal function is unstable or bleeding risk is high.
DOAC selection should be individualized according to renal function and clinical circumstances.
Always assess contraindications and situations requiring temporary interruption of anticoagulation.

Continuous learning and evidence based prescribing are essential for safe VTE management.”

Adil Aftab: Acute VTE Treatment and Anticoagulation Considerations in Renal Dysfunction